GoodRX, Weight Watchers, LifeMD Offering Novo Nordisk's New Weight-Loss Pill

Dow Jones01-05

By Connor Hart

GoodRX, Weight Watchers and LifeMD all said they will offer Novo Nordisk's new weight-loss pill, Wegovy, on their respective platforms.

U.S. regulators approved the new pill last month. At that time, Novo Nordisk said it planned to start selling the pill in the U.S. in early January, with a cash price of $149 a month for the starting dose.

Drug companies and analysts have said the pills will tap in to demand from people who don't want an injection or would prefer the cadence of a daily dose. Pills also offer the prospect of lower prices and better health-insurance coverage than injections, because pills cost less to make, The Wall Street Journal previously reported.

GoodRX, Weight Watchers and LifeMD all expanded their partnerships with Novo Nordisk to offer the new weight-loss pill through their respective platforms, a push to further expand access to popular GLP-1 treatments.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

January 05, 2026 08:42 ET (13:42 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601788497?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-05 21:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601788497","market":"fut","top_or_hot":-1,"title":"GoodRX, Weight Watchers, LifeMD Offering Novo Nordisk's New Weight-Loss Pill","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  GoodRX, Weight Watchers and LifeMD all said they will offer <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s new weight-loss pill, Wegovy, on their respective platforms. \n</p>\n<p>\n  U.S. regulators approved the new pill last month. At that time, Novo Nordisk said it planned to start selling the pill in the U.S. in early January, with a cash price of $149 a month for the starting dose. \n</p>\n<p>\n  Drug companies and analysts have said the pills will tap in to demand from people who don't want an injection or would prefer the cadence of a daily dose. Pills also offer the prospect of lower prices and better health-insurance coverage than injections, because pills cost less to make, The Wall Street Journal previously reported. \n</p>\n<p>\n  GoodRX, Weight Watchers and LifeMD all expanded their partnerships with Novo Nordisk to offer the new weight-loss pill through their respective platforms, a push to further expand access to popular GLP-1 treatments. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 05, 2026 08:42 ET (13:42 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GoodRX, Weight Watchers, LifeMD Offering Novo Nordisk's New Weight-Loss Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoodRX, Weight Watchers, LifeMD Offering Novo Nordisk's New Weight-Loss Pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-05 21:42</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  GoodRX, Weight Watchers and LifeMD all said they will offer <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s new weight-loss pill, Wegovy, on their respective platforms. \n</p>\n<p>\n  U.S. regulators approved the new pill last month. At that time, Novo Nordisk said it planned to start selling the pill in the U.S. in early January, with a cash price of $149 a month for the starting dose. \n</p>\n<p>\n  Drug companies and analysts have said the pills will tap in to demand from people who don't want an injection or would prefer the cadence of a daily dose. Pills also offer the prospect of lower prices and better health-insurance coverage than injections, because pills cost less to make, The Wall Street Journal previously reported. \n</p>\n<p>\n  GoodRX, Weight Watchers and LifeMD all expanded their partnerships with Novo Nordisk to offer the new weight-loss pill through their respective platforms, a push to further expand access to popular GLP-1 treatments. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 05, 2026 08:42 ET (13:42 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2601788497","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601788497","pubTimestamp":1767620520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"GoodRX, Weight Watchers and LifeMD all said they will offer Novo Nordisk's new weight-loss pill, Wegovy, on their respective platforms.U.S. regulators approved the new pill last month. At that time, Novo Nordisk said it planned to start selling the pill in the U.S. in early January, with a cash price of $149 a month for the starting dose.Drug companies and analysts have said the pills will tap in to demand from people who don't want an injection or would prefer the cadence of a daily dose. Pills also offer the prospect of lower prices and better health-insurance coverage than injections, because pills cost less to make, The Wall Street Journal previously reported.GoodRX, Weight Watchers and LifeMD all expanded their partnerships with Novo Nordisk to offer the new weight-loss pill through their respective platforms, a push to further expand access to popular GLP-1 treatments.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4167":"医疗保健技术","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4183":"个人用品","BK4532":"文艺复兴科技持仓","WW":"WW International, Inc.","BK4588":"碎股","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4585":"ETF&股票定投概念","LFMD":"LifeMD Inc.","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4599":"减肥药","BK4192":"特殊消费者服务","GDRX":"GoodRx Holdings, Inc."},"translate_title":"GoodRX、慧俪轻体、LifeMD提供诺和诺德的新型减肥药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LFMD":1.91,"GDRX":1.91,"WW":1.91},"content_text":"By Connor Hart \n\n\n \n\n\n  GoodRX, Weight Watchers and LifeMD all said they will offer Novo Nordisk's new weight-loss pill, Wegovy, on their respective platforms. \n\n\n  U.S. regulators approved the new pill last month. At that time, Novo Nordisk said it planned to start selling the pill in the U.S. in early January, with a cash price of $149 a month for the starting dose. \n\n\n  Drug companies and analysts have said the pills will tap in to demand from people who don't want an injection or would prefer the cadence of a daily dose. Pills also offer the prospect of lower prices and better health-insurance coverage than injections, because pills cost less to make, The Wall Street Journal previously reported. \n\n\n  GoodRX, Weight Watchers and LifeMD all expanded their partnerships with Novo Nordisk to offer the new weight-loss pill through their respective platforms, a push to further expand access to popular GLP-1 treatments. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 05, 2026 08:42 ET (13:42 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601788497","isCrawlerRequest":true}